Teva Boss Delights In European Progress
Better European Profits Help Pay Debts
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.
You may also be interested in...
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.